Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1271931 | 0.97 | TYR (0.39) | TYRHTTHPGDPIM1IDO1 | |
| SCHEMBL104124 | 0.76 | TYR (0.58) | TYRHTTHPGDIDO1MGLL | |
| SCHEMBL5487650 | 0.76 | — | — | |
| SCHEMBL1988819 | 0.74 | GABRA1 (0.33) | TYRHTTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL4445211 | 0.74 | TYR (0.41) | TYRHTTHPGDPIM1IDO1 | |
| SCHEMBL7033028 | 0.73 | CHRNA7 (0.33) | — | |
| SCHEMBL3395661 | 0.73 | — | — | |
| Ammonia Solution, Strong SCHEMBL7550588 | 0.73 | TYR (0.55) | TYRHTTHPGDIDO1MGLL | |
| Water SCHEMBL29278796 | 0.73 | TYR (0.55) | TYRHTTHPGDIDO1MGLL | |
| Water SCHEMBL11726962 | 0.73 | TYR (0.55) | TYRHTTHPGDIDO1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| WO-2021012479-A1 | HYDROGENATED CYCLIC [8] AROMATIC HYDROCARBON COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| WO-2021012478-A1 | HYDROGENATION ANNULE [12] AROMATIC COMPOUND AND PREPARATION METHOD THEREFOR | 清华大学 | 2021-01-28 | — | — | WO | claimed |
| CN-110372468-B | Hydrogenated endless [8] arene compound and preparation method thereof | 清华大学 | 2020-11-10 | — | — | CN | claimed |
| CN-110372469-B | Hydrogenated cyclo [12] arene compound and preparation method thereof | 清华大学 | 2020-09-08 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025032536-A1 | 1,3-DIAZA-4-OXA-[3.3.1]-BICYCLIC DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES, PARTICULARLY FOR THE TREATMENT OF OBESITY, DIABETES AND/OR NEURODEGENERATIVE DISEASES | UNIVERSITÀ DI PISA (IT) | 2025-02-13 | — | — | WO | disclosed |
| CN-115362153-B | Azaspiro compounds as monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-4217062-B1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-09 | — | — | EP | disclosed |
| WO-1998046602-A1 | ALKALOID HALIDE SALTS OF SWAINSONINE AND METHODS OF USE | GLYCODESIGN INC. (CA) | 1998-10-22 | — | — | WO | disclosed |
| WO-1997026873-A1 | ANTIMICROBIAL AURONE DERIVATIVES | PHYTERA, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-4900725-A | CONTRACEPTIVES | ROUSSEL UCLAF (FR) | 1990-02-13 | — | — | US | disclosed |
| US-3966801-A | ANTIINFLAMMATORY AGENTS | WILLIAM H. RORER, INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3965180-A | CNS DEPRESSANT | THE UPJOHN COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612379-B2 | Inhibitors of APOL1 and methods of using same | APOL1, RNASE1, LOXL1 | TYR 3872/4885HTT 2595/4885HPGD 3671/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | TYR 2111/4885HTT 4377/4885HPGD 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.